Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Net Margin (2020 - 2025)

Historic Net Margin for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to 13.13%.

  • Journey Medical's Net Margin rose 32100.0% to 13.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.48%, marking a year-over-year increase of 172600.0%. This contributed to the annual value of 26.14% for FY2024, which is 212700.0% down from last year.
  • According to the latest figures from Q3 2025, Journey Medical's Net Margin is 13.13%, which was up 32100.0% from 25.29% recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's Net Margin peaked at 48.61% during Q3 2023, and registered a low of 124.17% during Q4 2021.
  • Its 5-year average for Net Margin is 37.05%, with a median of 31.0% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by -1403100bps in 2021, then skyrocketed by 1111600bps in 2023.
  • Over the past 5 years, Journey Medical's Net Margin (Quarter) stood at 124.17% in 2021, then skyrocketed by 46bps to 66.65% in 2022, then skyrocketed by 79bps to 14.05% in 2023, then skyrocketed by 183bps to 11.62% in 2024, then plummeted by -213bps to 13.13% in 2025.
  • Its Net Margin was 13.13% in Q3 2025, compared to 25.29% in Q2 2025 and 31.0% in Q1 2025.